[
    {
        "content": "* Incyte announces initiation of pivotal clinical trial of Ruxolitinib (Jakafi\u00ae) for the treatment of essential thrombocythemia",
        "date": "11152017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte initiates clinical trial of Ruxolitinib for treatment of essential thrombocythemia "
    },
    {
        "content": "* Incyte reports 2017 third-quarter financial results and updates on key clinical programs",
        "date": "10312017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte says Q3 earnings per share $0.17 "
    },
    {
        "content": "* Incyte names new member to its board of directors Source text for Eikon: Further company coverage:",
        "date": "10302017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte Corp names new member to its board of directors "
    },
    {
        "content": "LONDON  Oct 31 AstraZeneca is stepping up its bet on immunotherapy combination treatments to fight lung cancer by signing a deal with Incyte under which the two companies will start a final-stage Phase III clinical trial next year.",
        "date": "10312017",
        "name": "Incyte Corporation",
        "news_type": "normal",
        "symbol": "INCY",
        "title": "AstraZeneca plans new pivotal lung cancer trial with Incyte "
    },
    {
        "content": "* Incyte and AstraZeneca to enter clinical trial collaboration in early lung cancer",
        "date": "10312017",
        "name": "Incyte Corporation",
        "news_type": "normal",
        "symbol": "INCY",
        "title": "BRIEF-Incyte and AstraZeneca to enter clinical trial collaboration in early lung cancer "
    },
    {
        "content": "* Incyte and MacroGenics announce global collaboration and licensing agreement for Anti-PD-1 Monoclonal Antibody MGA012",
        "date": "10252017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte and MacroGenics announce global collaboration and licensing agreement "
    },
    {
        "content": "* Concert Pharma says patent trials and appeal board of u.s. patent and trademark office has denied Incyte's petition to institute IPR\u200b Source text for Eikon: Further company coverage:",
        "date": "10192017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Concert Pharma Says PTAB denies Incyte petition challenging CTP-543 patent "
    },
    {
        "content": "Sept 22 The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab  saying additional clinical data is needed to further evaluate its safety  the company said on Friday.",
        "date": "09252017",
        "name": "Incyte Corporation",
        "news_type": "normal",
        "symbol": "INCY",
        "title": "CORRECTED-UPDATE 2-FDA declines to approve J&J arthritis drug sirukumab "
    },
    {
        "content": "* Baricitinib meets primary endpoint in phase 2 study of patients with moderate-to-severe atopic dermatitis",
        "date": "09142017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte's baricitinib meets primary endpoint in phase 2 study of patients with moderate-to-severe atopic dermatitis "
    },
    {
        "content": "* Incyte announces pricing of public offering of 4 945 000 shares of common stock Source text for Eikon: Further company coverage:",
        "date": "09082017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte announces pricing of public offering of 4 945 000 shares "
    },
    {
        "content": "* Incyte reports 2017 second-quarter financial results and updates on key clinical programs",
        "date": "08012017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte Q2 loss per share $0.06 "
    },
    {
        "content": "* Incyte Corp - \u200dlength of time to a resubmission for New Drug Application(NDA) anticipated to be a minimum of 18 months\u200b",
        "date": "07252017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Lilly and Incyte provide update on baricitinib "
    },
    {
        "content": "* Incyte announces first patient treated in Phase 3 clinical trial of itacitinib for acute graft-versus-host disease",
        "date": "07202017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte says first patient treated in Phase 3 clinical trial of itacitinib "
    },
    {
        "content": "* Japan ministry of health  labor and welfare (mhlw) grants marketing approval for olumiant\u00ae (baricitinib) for the treatment of rheumatoid arthritis",
        "date": "07032017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte says Japan Ministry of Health  Labor And Welfare grants marketing approval for Olumiant "
    },
    {
        "content": "* Updated data from Echo-202 trial of Incyte\u2019s Epacadostat in combination with Merck\u2019s Keytruda\u00ae (Pembrolizumab) demonstrate clinical activity across multiple tumor types",
        "date": "06052017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte Corp updates on Echo-202 trial of Incyte\u2019s Epacadostat in combination with Merck\u2019s Keytruda "
    },
    {
        "content": "A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small  ongoing study of patients with advanced lung cancer  according to data released on Wednesday.",
        "date": "05182017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "Merck  Incyte immunotherapy combination effective in lung cancer study "
    },
    {
        "content": "May 17 A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small  ongoing study of patients with advanced lung cancer  according to data released on Wednesday.",
        "date": "05172017",
        "name": "Incyte Corporation",
        "news_type": "normal",
        "symbol": "INCY",
        "title": "Merck  Incyte immunotherapy combination effective in lung cancer study "
    },
    {
        "content": "May 17 A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small  ongoing study of patients with advanced lung cancer  according to data released on Wednesday.",
        "date": "05172017",
        "name": "Incyte Corporation",
        "news_type": "normal",
        "symbol": "INCY",
        "title": "UPDATE 1-Merck  Incyte immunotherapy combination effective in lung cancer study "
    },
    {
        "content": "* Incyte reports 2017 first-quarter financial results and updates on key clinical programs",
        "date": "05042017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte Q1 loss per share $0.96 "
    },
    {
        "content": "April 21 A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron's experimental drug to treat rheumatoid arthritis.",
        "date": "04212017",
        "name": "Incyte Corporation",
        "news_type": "normal",
        "symbol": "INCY",
        "title": "EMA panel recommends nod for Sanofi  Regeneron's arthritis drug "
    },
    {
        "content": "* CEO Herv\u00e9 Hoppenot's 2016 total compensation was $11.8 million versus $5.9 million in 2015 - sec filing Source text - http://bit.ly/2nWbbhV Further company coverage:",
        "date": "04172017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte CEO's 2016 compensation was $11.8 mln "
    },
    {
        "content": "WASHINGTON  April 14 The U.S. Food and Drug Administration on Friday declined to approve a new drug for rheumatoid arthritis made by Eli Lilly and Co and partner Incyte Corp  the companies said on Friday.",
        "date": "04142017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "U.S. FDA declines to approve Eli Lilly and Incyte arthritis drug Olumiant "
    },
    {
        "content": "* Tetra Bio-pharma and Intelgenx announce the signing of a definitive agreement for the development and commercialization of a Dronabinol XL tablet",
        "date": "04032017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Tetra Bio-Pharma  Intelgenx sign agreement for development  commercialization of Dronabinol XL tablet "
    },
    {
        "content": "* Incyte and Merck provide additional details on previously announced collaboration investigating epacadostat and Keytruda\u00ae (pembrolizumab)",
        "date": "03312017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte and Merck provide additional details on previously announced collaboration "
    },
    {
        "content": "* Calithera to receive $12 million milestone payment from Incyte for achievement of pharmacokinetic and pharmacodynamic goals in Phase 1 study   Source text for Eikon:  Further company coverage:",
        "date": "03282017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Calithera to receive $12 mln milestone payment from Incyte "
    },
    {
        "content": "* S&P Dow Jones Indices - Incyte will replace Spectra Energy in the S&P 500 effective at the open of trading on February 28",
        "date": "02232017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte to replace Spectra Energy in S&P 500 "
    },
    {
        "content": "* Incyte Corp - amended agreement converts ongoing GITR and ox40 antibody programs from co-funded development and profit-sharing arrangements to royalty-bearing programs",
        "date": "02142017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte and Agenus amend collaboration agreement "
    },
    {
        "content": "* Incyte reports 2016 fourth-quarter and year-end financial results  provides 2017 financial guidance and updates on key clinical programs",
        "date": "02142017",
        "name": "Incyte Corporation",
        "news_type": "normal",
        "symbol": "INCY",
        "title": "BRIEF-Incyte reports Q4 earnings per share $0.05 "
    },
    {
        "content": "* European Commission approves once-daily olumiant tablets for treatment of adults with moderate-to-severe active rheumatoid arthritis",
        "date": "02132017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-European Commission approves once-daily olumiant tablets for treatment of rheumatoid arthritis "
    },
    {
        "content": "* Tetra Bio-Pharma Inc receives notice of authorization from Health Canada for the conduct of its clinical trial with its PPTGR topical product  Source text for Eikon:  Further company coverage:",
        "date": "02012017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Tetra Bio-Pharma receives notice of authorization from Health Canada "
    },
    {
        "content": "* INCYTE CORP REPORTS 7.4 PERCENT PASSIVE STAKE IN CALITHERA BIOSCIENCES INC AS OF JAN 30 - SEC FILING  Source text - (http://bit.ly/2kdJg8f) Further company coverage:",
        "date": "01312017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-INCYTE CORP REPORTS 7.4 PCT PASSIVE STAKE IN CALITHERA BIOSCIENCES "
    },
    {
        "content": "* Incyte and calithera biosciences announce global collaboration  to develop and commercialize CB-1158  a first-in-class  small molecule arginase inhibitor",
        "date": "01302017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte and Calithera Biosciences announce global collaboration  to develop and commercialize CB-1158 "
    },
    {
        "content": "* Merus announces closing of global strategic research collaboration with Incyte to discover and develop bispecific antibodies",
        "date": "01232017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Merus announces closing of global strategic research collaboration with Incyte "
    },
    {
        "content": "* Incyte and Merck to advance clinical development program investigating the combination of Epacadostat with Keytruda\u007f (pembrolizumab)",
        "date": "01092017",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte and Merck to advance clinical development program investigating the combination of Epacadostat with Keytruda "
    },
    {
        "content": "* Baricitinib demonstrates early response compared to placebo and significant improvement compared to Adalimumab in patient-reported outcomes",
        "date": "11142016",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Baricitinib demonstrates early response compared to placebo "
    },
    {
        "content": "* Eli lilly -new analyses of phase 3 trials show improvements in rheumatoid arthritis symptoms following treatment with Baricitinib  Source text for Eikon:  Further company coverage:",
        "date": "11142016",
        "name": "Incyte Corporation",
        "news_type": "normal",
        "symbol": "INCY",
        "title": "BRIEF-Eli lilly and Incyte says Baricitinib treatment show improvements in rheumatoid arthritis symptoms in phase 3 "
    },
    {
        "content": "* Sees fy research and development expenses $570 million-$580 million",
        "date": "11012016",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte Q3 earnings per share $0.19 "
    },
    {
        "content": "* Additional phase 1 data from ECHO-202 reinforce durability of response in patients with treatment-naive advanced or metastatic melanoma treated with epacadostat in combination with keytruda\u007f (pembrolizumab)",
        "date": "10072016",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte Corp provides additional Phase 1 Data from ECHO-202 trial "
    },
    {
        "content": "* GrowPros announces name change to Tetra Bio-Pharma Inc.  the closing of a non-brokered private placement  and extends warrants  Source text for Eikon:  Further company coverage:    ;))",
        "date": "09282016",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-GrowPros announces name change to Tetra Bio-Pharma Inc. "
    },
    {
        "content": "* Updated Phase 1 data reinforce the clinical profile of Epacadostat in combination with Keytruda\u007f (pembrolizumab)",
        "date": "09282016",
        "name": "Incyte Corporation",
        "news_type": "normal",
        "symbol": "INCY",
        "title": "BRIEF-Incyte corp - Epacadostat in combination with Pembrolizumab was well-tolerated "
    },
    {
        "content": "* Quarter financial results and updates key clinical programs",
        "date": "08092016",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte reported Q2 EPS $0.18 "
    },
    {
        "content": "* FDA grants breakthrough therapy designation for Incyte's Ruxolitinib (Jakafi\u007f) in acute Graft-Versus-Host disease (GVHD)  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom; +1 646 223 8780)",
        "date": "06232016",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-FDA grants breakthrough therapy designation for Incyte's Ruxolitinib "
    },
    {
        "content": "* First patient treated in echo-301 phase 3 study Incyte; expects initial data from echo-301 study to be available in 2018  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "06222016",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte announces first patient treated in ECHO-301 Phase 3 Study "
    },
    {
        "content": "* Says announced new 28-week data from phase 3 response-2 study of Jakafi",
        "date": "06102016",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte announces phase 3 data of Jakafi study "
    },
    {
        "content": "* On june 1  2016  amended buy-in license deal entered into by ariad pharmaceuticals  ariad pharmaceuticals (europe) s.a.r.l. & co",
        "date": "06012016",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte Corp amends buy-in license deal entered into by Ariad Pharmaceuticals "
    },
    {
        "content": "* Quarter financial results and updates shareholders on key clinical programs",
        "date": "05092016",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte Q1 earnings per share $0.12 "
    },
    {
        "content": "* Phase 3 study findings demonstrate treatment with baricitinib results in significant improvements for patients with rheumatoid arthritis who had inadequate response to biologics",
        "date": "03312016",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Incyte  Lilly provide detailed late-stage data on arthritis drug "
    },
    {
        "content": "* Baker Bros. Advisors LP reports 12.6 percent stake in Incyte Corp as of March 17  2016  - SEC filing  Source text: http://1.usa.gov/1SWMH00 Further company coverage:",
        "date": "03172016",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-Baker Bros Advisors reports 12.6 pct stake in Incyte Corp "
    },
    {
        "content": "Incyte Corp said it would stop testing its best-selling blood cancer drug  Jakafi  in solid tumor cancers after the treatment's effectiveness was found to be insufficient in a late-stage study  sending its shares down 16 percent premarket.",
        "date": "02112016",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "Incyte to discontinue testing Jakafi in solid tumor cancers "
    },
    {
        "content": "* Shares fall 16 pct to $60 premarket   (Adds analyst comment  details  updates shares)",
        "date": "02112016",
        "name": "Incyte Corporation",
        "news_type": "normal",
        "symbol": "INCY",
        "title": "UPDATE 2-Incyte to discontinue testing Jakafi in solid tumor cancers "
    },
    {
        "content": "Feb 11 Incyte Corp said it would discontinue a late-stage trial of its pancreatic cancer drug  ruxolitinib  after the treatment's effectiveness was shown to be insufficient.",
        "date": "02112016",
        "name": "Incyte Corporation",
        "news_type": "normal",
        "symbol": "INCY",
        "title": "Incyte to stop pancreatic cancer drug trial "
    },
    {
        "content": "Incyte Corp said on Wednesday that it would stop a mid-stage study on its combination treatment after it failed to prove to be sufficiently effective to treat metastatic colorectal cancer.",
        "date": "01272016",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "Incyte stops tests on Jakafi to treat colorectal cancer "
    },
    {
        "content": "Jan 27 Incyte Corp said on Wednesday that it would stop a mid-stage study on its combination treatment after it failed to prove to be sufficiently effective to treat metastatic colorectal cancer.",
        "date": "01272016",
        "name": "Incyte Corporation",
        "news_type": "normal",
        "symbol": "INCY",
        "title": "UPDATE 1-Incyte stops tests on Jakafi to treat colorectal cancer "
    },
    {
        "content": "Jan 27 Incyte Corp said on Wednesday that it would stop a mid-stage study on its combination cancer treatment after it failed to show sufficient levels of efficacy in an interim analysis.",
        "date": "01272016",
        "name": "Incyte Corporation",
        "news_type": "normal",
        "symbol": "INCY",
        "title": "Incyte stops mid-stage study of colorectal cancer treatment "
    },
    {
        "content": "* \u007f\u007fAstraZeneca and Incyte announce new lung cancer clinical trial collaboration\u007f",
        "date": "01112016",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "BRIEF-AstraZeneca \u007fand Incyte announce lung cancer clinical trial collaboration\u007f "
    },
    {
        "content": "Eli Lilly and Co and Incyte Corp said their experimental drug was found to be more effective in treating rheumatoid arthritis than a commonly prescribed medicine  in a late-stage study.",
        "date": "09292015",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "Lilly  Incyte arthritis drug found better than common treatment "
    },
    {
        "content": "Sept 29 Eli Lilly and Co and Incyte Corp  said their experimental drug was found to be more effective in treating rheumatoid arthritis than a commonly prescribed medicine  in a late-stage study.",
        "date": "09292015",
        "name": "Incyte Corporation",
        "news_type": "normal",
        "symbol": "INCY",
        "title": "UPDATE 1-Lilly  Incyte arthritis drug found better than common treatment "
    },
    {
        "content": "CTI BioPharma Corp's experimental blood cancer drug achieved the main goal of a late-stage study  but at least two analysts said the pill would not directly compete with Incyte Corp's treatment.",
        "date": "03092015",
        "name": "Incyte Corporation",
        "news_type": "topStory",
        "symbol": "INCY",
        "title": "CTI BioPharma blood cancer drug meets study goal "
    },
    {
        "content": "* Shares jump as much as 10.9 pct   (Adds analysts comments  background  updates shares)",
        "date": "03092015",
        "name": "Incyte Corporation",
        "news_type": "normal",
        "symbol": "INCY",
        "title": "UPDATE 2-CTI BioPharma blood cancer drug meets study goal "
    }
]